Clinical Trial Search

Primary: The Primary Symptom of GERD in Chinese Outpatients in Gastroenterology Department — 19; 30; 42; 23 Participants

Primary: Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment — -3.44 Days per week with symptoms

Primary: Patient-reported Symptom Response to Treatment Measured by the Reflux Symptom Index (RSI) Score — 15.5 score on a scale

Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00

Primary: Number of Participants Presenting Reflux Symptoms — 31; 8; 5 participants — p=<0.001

Primary: Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study. — 34.3; 10.4 Percentage of participants

Primary: The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period…

Primary: Changing Severity of Heart Burn of SSc Related Omeprazole Resistant GERD Evaluated by Visual Analogue Score (VAS) — 17.9; 17.2 VAS (100)

Primary: Number of Transient Lower Esophageal Sphincter Relaxations (TLESRs) 0-3 Hours Post Meal, Post Third Dose — 11.6; 15.5 Relaxations

Primary: Number of Participants With at Most One Day With Not More Than Mild Intensity of the Symptoms 'a Burning Feeling Behind the Breastbone' and 'Unpleasant Movement of…

Primary: The Number of Patients With Complete Resolution of Heartburn by Week 4 — 272; 302; 278 participants — p=<0.05

Primary: Patient's Assessment of Stanford Sleepiness Scale for the Last 24 Hours (Diaries) — 2.94; 2.62; 2.28; 2.03 Units on a scale

Primary: Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire. — 94.9; 87.3 percentage of participants

Primary: CLINICAL OUTCOME OF FEEDING SUCCESS — 33; 44 percentage of participants — p=0.28

Primary: Determination of Median Time to Sustained Partial Response as Defined by Reduction in Likert Severity Scale Used to Assess Pain Associated With Heartburn in the Patient…

Primary: TRPV1, GDNF, and NGF mRNA Expression of Esophageal Mucosa — 1.14; 3.25; 2.33; 1.39 Fold change

Primary: The Number of Reflux in GERD Patients — 33.6; 42.8; 81.0; 53.1 episodes — p=0.002

Primary: Association of Change in Patient's GSR From Beginning to End of Study Visit With GERD Symptom Severity 2 Weeks Later — -0.94; -1.70 micro-Siemens — p=0.034

Primary: Change in Reflux Disease Questionnaire Scores Administered at Baseline and 6 Weeks After Each Intervention — -1.2397; 0.0869 scores on a scale — p=0.0002

Primary: Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12…

Primary: Change From Baseline in Percent Regurgitation-Free Days Over Weeks 5-8 — 36.96; 43.01; 44.37; 38.79 percentage of days — p=0.128

Primary: Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period. — 174; 166; 156 Participants

Primary: Efficacy of Three Strategies of Long-term Treatment — 10.6; 7.8; 43 Percentage of participants with failure

Primary: Treatment-emergent Adverse Events Experienced by >=5% of Patients in Any Treatment Group — 3; 2; 3; 2 Participants

Primary: Subjective Symptom Improvement Rate — 75.7; 73.5; 68.6; 65.3 percentage of participants

Primary: Bradycardia Episodes/Day — 4.6; 3.6 episodes per day

Primary: Patient's Assessment of General Well-being During the Last 24 Hours (Diaries; ReQuest™ in Practice) — 5.31; 4.60; 3.67; 2.95 Units on a scale

Primary: To Evaluate the Incidence of All Adverse Events at Various Time Points. — 29 participants

Primary: Change in Weekly Gastroesophageal Reflux Disease (GERD) Symptom Scores (WGSS) — -0.89; 0.02; -0.47; -1.11 units on scale — p=<0.001

Primary: Symptom Frequency and Severity/Distress Scores From Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) (Overall) — 8.5; 5.2; 2.2; 1.0 score on a scale